Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd. (NASDAQ:EVGN) is a biotechnology company headquartered in Rehovot, Israel, specializing in the development of novel products for agriculture, food ingredients, and human microbiome-based therapeutics. Leveraging its proprietary Computational Predictive Biology (CPB) platform, Evogene integrates large-scale biological data with advanced computational tools to identify and optimize genes, microbial strains, and molecular traits. The company’s core focus encompasses seed traits for crop yield and quality improvement, microbial-based solutions for crop protection and plant health, and discovery of bioactive compounds targeting the human microbiome.

In the agricultural segment, Evogene’s pipeline includes seed trait projects designed to enhance drought tolerance, disease resistance, and nutrient use efficiency in major row crops such as corn, soybean, and canola. Its microbial product candidates aim to offer sustainable alternatives to chemical pesticides and fertilizers by harnessing beneficial bacteria and fungi. On the human health side, Evogene has spun off Biomica, a subsidiary focused on developing microbiome-based therapeutics for conditions such as inflammatory bowel disease and skin disorders, utilizing Evogene’s computational expertise to pinpoint therapeutic strains and bioactive molecules.

The company maintains strategic partnerships and collaborations with leading global agri-businesses and life sciences organizations to accelerate product development and commercialization. Notable collaborators include Bayer Crop Science, Bunge Limited, and International Flavors & Fragrances (IFF), working together on joint research programs and validation trials across North America, South America, Europe, and Asia. These alliances enable Evogene to access diverse field environments and regulatory expertise, positioning its pipeline for broader commercial adoption.

Founded in 2002, Evogene has grown from an academic spin-off into a publicly traded innovator in predictive biology. The leadership team is led by CEO Iris Braun, whose experience spans molecular biology, computational genomics, and product development. Supported by a multidisciplinary staff of computational scientists, molecular biologists, and agronomists, Evogene continues to expand its platform capabilities, aiming to deliver precise, data-driven solutions that address global challenges in agriculture, food security, and human health.

Key Stats

• Today's Range: $1.24 to $1.30
• 50-Day Range: $1.10 to $2.26
• 52-Week Range: $0.95 to $6.70
• Volume: 165,522 shs
• Average Volume: 629,368 shs
• Market Capitalization: $6.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Buy

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evogene has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.54% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 56.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.54% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 56.02%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Evogene has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Evogene this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

Only 10.40% of the stock of Evogene is held by institutions.

EVGN Stock Analysis - Frequently Asked Questions

How have EVGN shares performed this year?

Evogene's stock was trading at $1.87 at the start of the year. Since then, EVGN stock has decreased by 32.6% and is now trading at $1.26.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) issued its earnings results on Wednesday, May, 21st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.12. The biotechnology company earned $2.44 million during the quarter, compared to analysts' expectations of $4.42 million. Evogene had a negative net margin of 224.82% and a negative trailing twelve-month return on equity of 102.40%.
Read the conference call transcript.

When did Evogene's stock split?

Shares of Evogene reverse split on the morning of Thursday, July 25th 2024.The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Plug Power (PLUG), Riot Platforms (RIOT) and AquaBounty Technologies (AQB).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:EVGN
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Evogene: $3.50
• High Price Target: $3.50
• Low Price Target: $3.50
• Potential Upside/Downside: +177.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.49 million
• Net Margins: -224.82%
• Pretax Margin: -254.09%
• Return on Equity: -102.40%
• Return on Assets: -39.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.06
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: $6.77 million
• Price / Sales: 1.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.77 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 5,365,000
• Free Float: 4,968,000
• Market Cap: $6.76 million
• Optionable: Optionable
• Beta: 1.58